Sandostatin LAR now recommended for midgut tumours

Sandostatin LAR (octreotide), a synthetic derivative of somatostatin, is now also licensed for use in the treatment of advanced neuroendocrine tumours (NETs) of the midgut and where non-midgut sites of origin have been excluded but the primary origin is unknown.

In the double-blind, phase IIIb PROMID study (n=85), treatment-naïve patients with well-differentiated metastatic midgut NETs were randomised to receive monthly intramuscular octreotide LAR 30mg injections or placebo, using time to tumour progression (TTP) as the primary endpoint.

Median TTP was over twice as long for patients receiving octreotide as for those receiving placebo group: 14.3 months versus 6 months (hazard ratio 0.34; 95% CI 0.20-0.59; p<0.000072). However, this TTP increase was not associated with a significant difference in survival between the groups.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more